Key Points
- Teladoc Health CEO Charles Divita III sold 19,132 shares on June 2 at an average price of $7.63, totaling about $145,977. The sale reduced his ownership by 4.68% and was reported as covering tax withholding tied to vesting equity awards.
- The company’s recent quarterly results were mixed: Teladoc posted a loss of $0.36 per share, slightly worse than expectations, while revenue of $613.85 million came in above estimates. Revenue was still down 2.5% year over year, and the company continues to guide for losses in 2026.
- Wall Street remains cautious on TDOC, with a consensus rating of “Hold” and an average price target of $7.43. Several firms recently cut targets, even as institutional investors still hold a large majority of the stock.
Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) insider Fernando Rodrigues sold 5,677 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $43,315.51. Following the transaction, the insider directly owned 9,572 shares of the company's stock, valued at approximately $73,034.36. This trade represents a 37.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Teladoc Health Trading Down 6.1%
Shares of NYSE TDOC opened at $7.08 on Thursday. Teladoc Health, Inc. has a 1 year low of $4.40 and a 1 year high of $9.77. The stock has a market cap of $1.28 billion, a P/E ratio of -7.30 and a beta of 2.14. The firm has a 50-day moving average of $6.13 and a 200 day moving average of $6.21. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72.
Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The business had revenue of $613.85 million for the quarter, compared to analysts' expectations of $611.04 million. During the same period last year, the business earned ($0.53) earnings per share. The company's revenue was down 2.5% on a year-over-year basis. Teladoc Health has set its FY 2026 guidance at -1.050--0.750 EPS and its Q2 2026 guidance at -0.300--0.200 EPS. As a group, sell-side analysts expect that Teladoc Health, Inc. will post -0.91 EPS for the current fiscal year.
Institutional Trading of Teladoc Health
A number of large investors have recently made changes to their positions in the stock. Federated Hermes Inc. boosted its holdings in shares of Teladoc Health by 0.5% in the third quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider's stock worth $2,379,000 after buying an additional 1,450 shares during the last quarter. Creative Planning boosted its holdings in shares of Teladoc Health by 7.7% in the third quarter. Creative Planning now owns 20,567 shares of the health services provider's stock worth $159,000 after buying an additional 1,462 shares during the last quarter. Krane Funds Advisors LLC lifted its holdings in Teladoc Health by 13.4% during the third quarter. Krane Funds Advisors LLC now owns 12,431 shares of the health services provider's stock valued at $106,000 after purchasing an additional 1,469 shares in the last quarter. State of Wyoming lifted its holdings in Teladoc Health by 2.1% during the third quarter. State of Wyoming now owns 79,075 shares of the health services provider's stock valued at $611,000 after purchasing an additional 1,628 shares in the last quarter. Finally, Syon Capital LLC lifted its holdings in Teladoc Health by 19.1% during the fourth quarter. Syon Capital LLC now owns 14,140 shares of the health services provider's stock valued at $99,000 after purchasing an additional 2,264 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of analysts have weighed in on the stock. Stifel Nicolaus reduced their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Thursday, February 26th. BMO Capital Markets reduced their price objective on shares of Teladoc Health from $8.00 to $5.00 and set a "market perform" rating for the company in a research note on Thursday, February 26th. Piper Sandler restated an "overweight" rating and set a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research note on Thursday, February 26th. JPMorgan Chase & Co. reduced their price objective on shares of Teladoc Health from $9.00 to $7.00 and set a "neutral" rating for the company in a research note on Friday, March 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Teladoc Health from a "hold" rating to a "buy" rating and set a $11.00 price objective for the company in a research note on Tuesday, March 10th. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Teladoc Health presently has an average rating of "Hold" and an average target price of $7.43.
Read Our Latest Report on Teladoc Health
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
